Dr. Marcelo Bigal, President and CEO of Ventus Therapeutics, a company that expects to become the leader in the field of using precision medicine to identify subsets of patients with severe chronic neurological conditions. Prior to Ventus, Dr. Marcelo held multiple positions in the industry, including CSO at Teva, leading a group of over 1,300 people, as well as CMO of Purdue. Prior to Teva, he was also the CMO at Labrys Biologics, Inc., leading the team responsible for the development of Fremanezumab (approved as Ajovy), a humanized monoclonal antibody against CGRP, an anti-migraine and pain target. He has published over 322 peer-reviewed articles in indexed journals, edited six books, and authored / co-authored 35 book chapters in the field of neurology.

--- Send in a voice message: https://podcasters.spotify.com/pod/show/the-executive/message